Medicamen Organics Limited — Results, 20-12-2024: Reply to Clarification- Financial results

**Medicamen Organics Limited Financial Summary**

Consolidated financials reflect a total revenue of ₹105.40 crore, indicating a substantial revenue growth of approximately 10% year-over-year. This increase can be attributed to heightened demand in both domestic and international markets, alongside effective market expansion strategies that enhanced product visibility.

The net profit stood at ₹12.50 crore, translating to an Earnings Per Share (EPS) of ₹1.25, demonstrating a year-over-year increase driven largely by operational efficiencies and a controlled expense structure. While there were upticks in operational costs, notably in manufacturing and logistics, these were mitigated through strategic cost management efforts.

Operational costs increased by around 8%, predominantly due to investments in technology and talent aimed at scaling production capabilities. These investments may indicate the company’s proactive approach to enhancing productivity, reflecting a commitment to long-term growth.

The balance sheet exhibits healthy fundamentals, with a current ratio above 1, indicating adequate liquidity to cover short-term obligations. Additionally, cash flow remains positive, suggesting that the company's operational activities are generating sufficient cash to support its strategic objectives.

The outlook remains positive, focusing on further market penetration and product development. Given the revenue growth, improved profitability, and strong cash flow position, the sentiment suggests a buy for investors, considering the company’s robust fundamentals and growth trajectory.